rdf:type |
|
lifeskim:mentions |
|
pubmed:dateCreated |
1991-3-8
|
pubmed:abstractText |
Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t.i.d.) treatment. Metabolic control and daily insulin dose did not change in any patient during the study. The insulin-mediated glucose uptake during the clamp studies showed no variation after placebo or ibopamine therapy. Total cholesterol, HDL-cholesterol and triglycerides concentrations remained unchanged. This study clearly suggests that ibopamine administered at a daily dose of 300 mg for 3 weeks presents a metabolic safety in type I diabetic patients.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0008-6312
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
77 Suppl 5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
63-6
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2279254-Adult,
pubmed-meshheading:2279254-Blood Glucose,
pubmed-meshheading:2279254-Cardiotonic Agents,
pubmed-meshheading:2279254-Deoxyepinephrine,
pubmed-meshheading:2279254-Diabetes Mellitus, Type 1,
pubmed-meshheading:2279254-Female,
pubmed-meshheading:2279254-Heart Failure,
pubmed-meshheading:2279254-Humans,
pubmed-meshheading:2279254-Insulin,
pubmed-meshheading:2279254-Insulin Resistance,
pubmed-meshheading:2279254-Male,
pubmed-meshheading:2279254-Middle Aged,
pubmed-meshheading:2279254-Vasodilator Agents
|
pubmed:year |
1990
|
pubmed:articleTitle |
Ibopamine does not affect insulin resistance in patients with type I diabetes.
|
pubmed:affiliation |
Chair of Metabolic Disease, University of Pisa, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|